Viatris to Buy Pacira BioSciences for $1.65 Billion
Viatris is expanding its innovative medicines strategy by acquiring Pacira BioSciences for $1.65 billion to lead in non-opioid pain therapies.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Viatris has reached an agreement to acquire Pacira BioSciences in a deal valued at $1.65 billion. This strategic acquisition is designed to integrate Pacira's non-opioid pain pipeline into the Viatris portfolio. According to an official statement from the Viatris Newsroom, the move is intended to advance the company's innovative medicines strategy and establish Viatris as a leader in the field of non-opioid pain therapies. The deal represents a significant financial commitment to shift the company's focus toward alternative pain management solutions. Coverage of the acquisition is widespread across major financial and industry publications. The Wall Street Journal and Reuters both report the $1.65 billion price tag, emphasizing that Viatris is effectively betting on non-opioid pain drugs.
Fierce Pharma highlights the specific goal of snapping up Pacira's non-opioid pain pipeline. Meanwhile, Barron's focuses on how this acquisition allows Viatris to sharpen its focus on painkillers that do not rely on opioids, and The Motley Fool reports that Pacira BioSciences' stock skyrocketed following the announcement of the deal. To understand the current stakes, the coverage indicates that this move is part of a broader strategy to move toward innovative medicines. By targeting the non-opioid sector, Viatris is positioning itself to address pain management through a pipeline that avoids traditional opioids. This transition is framed by the Viatris Newsroom as a key step in becoming a leader in this specific therapeutic area. The reaction from the market, as noted by The Motley Fool, suggests high investor interest in the valuation and the potential of the Pacira pipeline.
Future developments to watch include the integration of the Pacira pipeline into the existing Viatris infrastructure. While the financial terms of the $1.65 billion deal are clear, coverage does not yet specify the exact timeline for the completion of the acquisition. Market observers will likely track the continued performance of Pacira's stock and the subsequent rollout of the non-opioid therapies that Viatris intends to lead with. The success of this innovative medicines strategy will depend on the development of the acquired pipeline.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 39d ago.
Quick answers
How much is Viatris paying for Pacira BioSciences?
Viatris has agreed to acquire Pacira BioSciences for $1.65 billion.
What is the primary goal of this acquisition?
Viatris aims to advance its innovative medicines strategy and become a leader in non-opioid pain therapies.
How did the market react to the news?
According to The Motley Fool, Pacira BioSciences' stock skyrocketed today following the news.
Coverage (11)
- Viatris Focuses on Non-Opioid Painkillers With Pacira BioSciences Acquisition Barron's · 39d ago
- Why Pacira BioSciences Skyrocketed Today The Motley Fool · 39d ago
- Viatris to snap up Pacira's non-opioid pain pipeline for $1.65B Fierce Pharma · 39d ago
- Viatris bets on non-opioid pain drugs with $1.65 billion Pacira deal Reuters · 39d ago
- Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies Viatris Newsroom · 39d ago
- Viatris to Buy Pacira BioSciences for $1.65 Billion WSJ · 39d ago
- Small Biotech Catapults On $1.65 Billion Takeover Deal Investor's Business Daily · 39d ago
- Viatris is buying Pacira BioSciences for $1.65 billion in non-opioid pain push Quartz · 39d ago
- Viatris bets on non-opioid pain drugs with $1.65 billion Pacira deal KSL News · 39d ago
- Pacira BioSciences downgraded after Viatris ann... Pluang · 39d ago
- PCRX SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES PACIRA BIOSCIENCES, INC. Morningstar · 39d ago
Topics
Related trends
Millions of Americans are not taking their GLP-1 drugs as prescribed
Nearly half of U.S. GLP-1 users are altering prescribed dosing, with cost and side effects driving widespread non-adherence.
Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drug
A former Eli Lilly sales representative has filed a retaliation lawsuit alleging she was fired for objecting to Mounjaro marketing.
Argenx to acquire Unnatural Products in deal worth up to $1.15B
Argenx agrees to acquire Unnatural Products for up to $1.15 billion, betting on AI-guided macrocycle technology to expand oral peptide drug development.
Revolution Medicines’ pancreatic cancer drug has stunning commercial debut
Revolution Medicines' pancreatic cancer drug Rasonque achieves an eye-popping commercial debut, shattering analyst estimates.
Novo Nordisk Lifts Guidance as Rollout of Wegovy Weight-Loss Pill Continues
Novo Nordisk raises its 2026 outlook and shares surge as the Wegovy weight-loss pill rollout accelerates.
Pfizer hikes full-year outlook as newer products grow, taps company veteran as new CFO
Pfizer has increased its 2026 full-year guidance following strong third-quarter results driven by growth in cancer and migraine medications.